Bendamustine + Rituximab (BR), 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-RITUXIMAB` `DRUG-BENDAMUSTINE`

ID	`REG-BR-STANDARD`
Type	Regimen
Status	reviewed 2026-04-24 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MZL-2024` `SRC-NCCN-BCELL-2025`

Notes

Standard chemoimmunotherapy regimen for indolent B-cell lymphomas. In HCV-MZL, reserved for cases that are non-responsive to antiviral therapy or have aggressive/bulky disease at presentation requiring immediate cytoreduction.

Used By

Contraindications

CI-HBV-NO-PROPHYLAXIS - CI-HBV-NO-PROPHYLAXIS
CI-SEVERE-CYTOPENIA-BR - CI-SEVERE-CYTOPENIA-BR

Drug

DRUG-BENDAMUSTINE - Bendamustine

Indication

IND-FL-1L-BR - IND-FL-1L-BR
IND-HCV-MZL-1L-BR-AGGRESSIVE - IND-HCV-MZL-1L-BR-AGGRESSIVE
IND-NMZL-1L-BR - IND-NMZL-1L-BR

Monitoring

MON-BR-REGIMEN - MON-BR-REGIMEN

Regimen

REG-DAA-OBSERVATION-HCV-MZL - Post-DAA active surveillance for HCV-MZL (after SVR12)

Supportive Care

SUP-ANTIEMETIC-PREMED - Antiemetic premedication for moderately emetogenic chemotherapy
SUP-GCSF-NEUTROPENIA - G-CSF support for neutropenia
SUP-PJP-PROPHYLAXIS - Pneumocystis jirovecii prophylaxis
SUP-TLS-PROPHYLAXIS - Tumor lysis syndrome prophylaxis

Tests

TEST-FIB4 - FIB-4 Index